{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:21:36Z","timestamp":1792120896013,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T00:00:00Z","timestamp":1390348800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s10157-014-0935-8","type":"journal-article","created":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T07:22:57Z","timestamp":1390288977000},"page":"876-884","source":"Crossref","is-referenced-by-count":132,"title":["Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout"],"prefix":"10.1007","volume":"18","author":[{"given":"Tatsuo","family":"Hosoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwao","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Hisatome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunya","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeko","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,22]]},"reference":[{"key":"935_CR1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008. Am J Med. 2012;125:679\u201387.","journal-title":"Am J Med"},{"key":"935_CR2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1291\/hypres.24.691","volume":"24","author":"K Iseki","year":"2001","unstructured":"Iseki K, Oshiro S, Tozawa M, et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691\u20137.","journal-title":"Hypertens Res"},{"key":"935_CR3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.ajkd.2007.05.013","volume":"50","author":"M Chonchol","year":"2007","unstructured":"Chonchol M, Shlipak MG, Katz R, Sarnak M, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50:239\u201347.","journal-title":"Am J Kidney Dis"},{"key":"935_CR4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MAJ.0b013e3181db6e16","volume":"339","author":"HY Chang","year":"2010","unstructured":"Chang HY, Tung CW, Lee PH, et al. Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci. 2010;339:509\u201315.","journal-title":"Am J Med Sci"},{"key":"935_CR5","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","volume":"30","author":"H Yamanaka","year":"2011","unstructured":"Yamanaka H, Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30:1018\u201329.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"935_CR6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2008.05.022","volume":"202","author":"AC Gagliardi","year":"2009","unstructured":"Gagliardi AC, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis. 2009;202:11\u20137.","journal-title":"Atherosclerosis"},{"key":"935_CR7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.amjmed.2006.06.040","volume":"120","author":"HK Choi","year":"2007","unstructured":"Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442\u20137.","journal-title":"Am J Med"},{"key":"935_CR8","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2337\/dc09-0288","volume":"32","author":"S Kodama","year":"2009","unstructured":"Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32:1737\u201342.","journal-title":"Diabetes Care"},{"key":"935_CR9","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/MNH.0b013e328330d9d0","volume":"18","author":"DI Feig","year":"2009","unstructured":"Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens. 2009;18:526\u201330.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"935_CR10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"YP Siu","year":"2006","unstructured":"Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51\u20139.","journal-title":"Am J Kidney Dis"},{"key":"935_CR11","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","volume":"5","author":"M Goicoechea","year":"2010","unstructured":"Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388\u201393.","journal-title":"Clin J Am Soc Nephrol"},{"key":"935_CR12","unstructured":"Collins AJ, Foley RN, Chavers B et al. \u2018United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis. 2012; 59(1 Suppl 1):A7, e1\u2013420."},{"key":"935_CR13","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1074\/jbc.M208307200","volume":"278","author":"K Okamoto","year":"2003","unstructured":"Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003;278:1848\u201355.","journal-title":"J Biol Chem"},{"key":"935_CR14","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1073\/pnas.0400973101","volume":"101","author":"K Okamoto","year":"2004","unstructured":"Okamoto K, Matsumoto K, Hille R, et al. The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition. Proc Natl Acad Sci USA. 2004;101:7931\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"935_CR15","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthr Care Res (Hoboken). 2012;64:1431\u201346.","journal-title":"Arthr Care Res (Hoboken)"},{"key":"935_CR16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","volume":"27","author":"F Arellano","year":"1993","unstructured":"Arellano F, Sacrist\u00e1n JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993;27:337\u201343.","journal-title":"Ann Pharmacother"},{"key":"935_CR17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/rheumatology\/26.6.445","volume":"26","author":"BT Emmerson","year":"1987","unstructured":"Emmerson BT, Gordon RB, Cross M, et al. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol. 1987;26:445\u20139.","journal-title":"Br J Rheumatol"},{"key":"935_CR18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47\u201356.","journal-title":"Am J Med"},{"key":"935_CR19","first-page":"1646","volume":"33","author":"N Dalbeth","year":"2006","unstructured":"Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646\u201350.","journal-title":"J Rheumatol"},{"key":"935_CR20","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthr Rheum. 2008;59:1540\u20138.","journal-title":"Arthr Rheum"},{"key":"935_CR21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.semarthrit.2012.03.013","volume":"42","author":"RV Curiel","year":"2012","unstructured":"Curiel RV, Guzman NJ. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. Semin Arthr Rheum. 2012;42:166\u201378.","journal-title":"Semin Arthr Rheum"},{"key":"935_CR22","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1016\/j.bmcl.2009.08.091","volume":"19","author":"T Sato","year":"2009","unstructured":"Sato T, Ashizawa N, Matsumoto K, et al. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051\u2014a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia (corrected). Bioorg Med Chem Lett. 2009;19:6225\u20139.","journal-title":"Bioorg Med Chem Lett"},{"key":"935_CR23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1124\/jpet.110.174540","volume":"336","author":"K Matsumoto","year":"2011","unstructured":"Matsumoto K, Okamoto K, Ashizawa N, et al. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther. 2011;336:95\u2013103.","journal-title":"J Pharmacol Exp Ther"},{"key":"935_CR24","doi-asserted-by":"crossref","first-page":"F481","DOI":"10.1152\/ajprenal.00092.2009","volume":"297","author":"T Kosugi","year":"2009","unstructured":"Kosugi T, Nakayama T, Heinig M, et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db\/db mice. Am J Physiol Renal Physiol. 2009;297:F481\u20138.","journal-title":"Am J Physiol Renal Physiol"},{"key":"935_CR25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10157-012-0609-3","volume":"16","author":"H Omori","year":"2012","unstructured":"Omori H, Kawada N, Inoue K, et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol. 2012;16:549\u201356.","journal-title":"Clin Exp Nephrol"},{"key":"935_CR26","first-page":"62","volume":"29","author":"WY Ng","year":"2000","unstructured":"Ng WY, Lui KF, Thai AC. Evaluation of a rapid screening test for microalbuminuria with a spot measurement of urine albumin-creatinine ratio. Ann Acad Med Singap. 2000;29:62\u20135.","journal-title":"Ann Acad Med Singap"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-014-0935-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-014-0935-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-014-0935-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T21:18:11Z","timestamp":1565126291000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-014-0935-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,22]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["935"],"URL":"https:\/\/doi.org\/10.1007\/s10157-014-0935-8","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,22]]}}}